0000000000333713

AUTHOR

Stefano Aliberti

showing 10 related works from this author

Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control Study

2022

High-flow nasal therapy (HFNT) provides several pathophysiological benefits in chronic respiratory disorders. We aimed to evaluate the effectiveness of long-term HFNT in patients with bronchiectasis (BE). Methods: This is a retrospective bicentric case-control study of outpatients with BE on optimized medical treatment with a severe exacerbation requiring hospitalization in the previous year. Patients on long-term home HFNT (cases) and patients on optimized medical treatment alone (controls) were matched by age, sex, bronchiectasis severity index, and exacerbations in the previous year. Data on BE exacerbations, hospitalizations/year, mucus features, respiratory symptoms, and pulmonary func…

bronchiectasis; exacerbation; high-flow nasal cannula; high-flow nasal therapy; hospitalization; mucus;exacerbationbronchiectasis; exacerbation; high-flow nasal cannula; high-flow nasal therapy; hospitalization; mucushigh-flow nasal cannulahigh-flow nasal cannula; high-flow nasal therapy; bronchiectasis; mucus; exacerbation; hospitalizationbronchiectasismucusSettore MED/10 - Malattie dell'Apparato Respiratoriohigh-flow nasal therapyGeneral Medicinehospitalization
researchProduct

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

2020

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored al…

ISAR International Severe Asthma RegistrySHARPPediatricsSevere asthmaSA severe asthmaBiologics Oral corticosteroids Real-life Registr Severe asthmaOmalizumabforced expiratory volume in the 1st secondFood &ampGrading of Recommendations Assessmentchronic rhinosinusitis with nasal polyposisFEV1chemistry.chemical_compound0302 clinical medicineQuality of lifeEMAReal WorldEuropean Medicines AgencyBiologics; Oral corticosteroids; Real-life; Registr; Severe asthmaOral corticosteroidsFDA Food & Drug AdministrationImmunology and Allergy030223 otorhinolaryngologySevere Heterogeneous Asthma Research collaborationmusculoskeletal neural and ocular physiologyReal-lifeCRSwNPOCSsBenralizumabDupilumabCRSwNP chronic rhinosinusitis with nasal polyposisGRADESHARP Severe Heterogeneous Asthma Research collaboration Patient-centredSevere Asthma Network in ItalyFDAmedicine.drugPulmonary and Respiratory Medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyDrug AdministrationGINA Global Initiative for AsthmaRW Real WorldImmunologymacromolecular substancesRWSettore MED/10 - Malattie Dell'Apparato RespiratorioBiologicsInternational Severe Asthma RegistryISAR03 medical and health sciencesSADisease registrySARP Severe Asthma Research ProgramPatient-centredmedicineAsthmabusiness.industrySettore MED/09 - MEDICINA INTERNASANI Severe Asthma Network in ItalySANIBiological productmedicine.diseaseOCSs Oral CorticoSteroidsGINASARPSevere Asthma Research ProgramFEV1 forced expiratory volume in the 1st second030228 respiratory systemchemistrynervous systemRegistrEMA European Medicines AgencyDevelopment and EvaluationSevere asthma Biologics Oral corticosteroids Real-life Registrbusinesslcsh:RC581-607Global Initiative for AsthmaMepolizumabGRADE Grading of Recommendations Assessment Development and Evaluation
researchProduct

Integrated longitudinal immunophenotypic, transcriptional, and repertoire analyses delineate immune responses in patients with COVID-19

2021

To understand how a protective immune response against SARS-CoV-2 develops over time, we integrated phenotypic, transcriptional and repertoire analyses on PBMCs from mild and severe COVID-19 patients during and after infection, and compared them to healthy donors (HD). A type I IFN-response signature marked all the immune populations from severe patients during the infection. Humoral immunity was dominated by IgG production primarily against the RBD and N proteins, with neutralizing antibody titers increasing post infection and with disease severity. Memory B cells, including an atypical FCRL5+ T-BET+ memory subset, increased during the infection, especially in patients with mild disease. A…

education.field_of_studybiologyT cellImmunologyPopulationGeneral MedicineGZMBImmune systemImmunophenotypingmedicine.anatomical_structureHumoral immunityImmunologybiology.proteinmedicineAntibodyeducationCD8Science Immunology
researchProduct

Validation of Murray sputum purulence scale in the Italian Registry of Bronchiectasis (IRIDE)

2018

Introduction: Murray sputum colour chart stratifies patients according to the presence of mucous (M), muco-purulent (MP) or purulent (P) sputum, and has not been validated in Bx yet. We aimed to validate this scale across a large Italian cohort of Bx patients. Methods: A secondary analysis of the IRIDE database was conducted including adults with Bx and daily sputum production enrolled across 13 Italian centres between 2014 and 2017. M vs. MP vs. P sputum producers were identified and clinical, functional and microbiological data were collected. Clinical outcomes during a two-year follow up period were evaluated in the Monza and Milan cohorts. A sensitivity analysis excluding COPD patients …

medicine.medical_specialtyBronchiectasisSputum colourCopd patientsbusiness.industrySputum Productionmedicine.diseaseDisease severityInternal medicineSecondary analysisCohortmedicineSputummedicine.symptombusiness
researchProduct

Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study

2018

This study aimed to describe real-life microbiological testing of adults hospitalised with community-acquired pneumonia (CAP) and to assess concordance with the 2007 Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) and 2011 European Respiratory Society (ERS) CAP guidelines. This was a cohort study based on the Global Initiative for Methicillin-resistant Staphylococcus aureus Pneumonia (GLIMP) database, which contains point-prevalence data on adults hospitalised with CAP across 54 countries during 2015. In total, 3702 patients were included. Testing was performed in 3217 patients, and included blood culture (71.1%), sputum culture (61.8%), Legionella urinary anti…

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtycommunity-acquired pneumoniaCommunity-acquired pneumoniaPatients4Concordance030106 microbiologyRespiratory Systemlcsh:MedicineSettore MED/10 - Malattie Dell'Apparato RespiratorioGUIDELINESPneumònia adquirida a la comunitatSputum cultureSerology03 medical and health sciences0302 clinical medicineCommunity-acquired pneumoniaInternal medicinemedicineMANAGEMENTBlood culture030212 general & internal medicinePOPULATIONpneumonia Methicillin-resistant Staphylococcus aureus PneumoniaScience & Technologymedicine.diagnostic_testbusiness.industryMORTALITYlcsh:RMicrobiologia mèdicaOriginal ArticlesGuidelinePneumoniaMedical microbiologymedicine.diseaseMicrobiologicalETIOLOGYPneumoniaDiagnostic testingREQUIRING HOSPITALIZATIONbusinessLife Sciences & BiomedicineCohort studyERJ Open Research
researchProduct

Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia

2021

Background: Aspiration community-acquired pneumonia (ACAP) and community-acquired pneumonia (CAP) in patients with aspiration risk factors (AspRFs) are infections associated with anaerobes, but limited evidence suggests their pathogenic role. Research Question: What are the aspiration risk factors, microbiology patterns, and empiric anti-anaerobic use in patients hospitalized with CAP? Study Design and Methods: This is a secondary analysis of GLIMP, an international, multicenter, point-prevalence study of adults hospitalized with CAP. Patients were stratified into three groups: (1) ACAP, (2) CAP/AspRF+ (CAP with AspRF), and (3) CAP/AspRF- (CAP without AspRF). Data on demographics, comorbidi…

MalePulmonary and Respiratory Medicinemedicine.drug_classAspiration riskAntibioticsNursing home residentSettore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care MedicineMicrobiologyanaerobic; aspiration; bacteria; pneumonia; risk factors.Cohort Studies03 medical and health sciences0302 clinical medicineCommunity-acquired pneumoniaTaverneAnti-Bacterial AgentmedicineHumanspneumoniarisk factors.Community-Acquired Infection030212 general & internal medicinebacteriaStrokeAgedAged 80 and overaspirationbusiness.industryRespiratory AspirationMiddle Agedmedicine.diseaseAntibiotic coverageAnti-Bacterial AgentsCommunity-Acquired InfectionsHospitalizationPneumonia030228 respiratory systemRisk factorsrisk factoranaerobicFemaleUnderweightmedicine.symptombusinessCardiology and Cardiovascular Medicine
researchProduct

Additional file 1: of Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective

2018

Table A: Tables with testing frequencies for specific atypical pathogens across continents (A1: Testing frequencies for C. pneumoniae across continents; A2: Testing frequencies for M. pneumoniae across continents; A3: Testing frequencies for L. pneumophila across continents).- Brief description of the data: a table in three parts reporting data about frequency of testing for different atypical pathogens across different continents. (DOC 50â kb)

researchProduct

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

2018

Abstract Background The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia. Methods We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor. Results At least 1 risk factor for immunocompromis…

0301 basic medicineMalePediatricsEtiologyMultidrug-resistant pathogenMRSAPneumocystis pneumoniaPneumònia adquirida a la comunitatHOSPITALIZED-PATIENTS0302 clinical medicineCommunity-acquired pneumoniaRisk FactorsPrevalenceMedicine030212 general & internal medicinePNEUMOCYSTIS PNEUMONIAArticles and CommentariesAged 80 and overRespiratory tract infectionsAnemia AplasticMiddle Aged3. Good healthCommunity-Acquired InfectionsEuropeInfectious DiseasesImmunocompromise; Microbiology; MRSA; Multidrug-resistant pathogens; PneumoniaEtiologiaHematologic NeoplasmsFemaleBLOOD-STREAM INFECTIONSLung TransplantationMicrobiology (medical)medicine.medical_specialtyAsiaNeutropeniaCommunity-acquired pneumonia030106 microbiologyRESPIRATORY-TRACT INFECTIONSHematologic NeoplasmsSettore MED/10 - Malattie Dell'Apparato RespiratorioTRANSPLANT RECIPIENTSDISEASES-SOCIETYMicrobiology03 medical and health sciencesImmunocompromised HostPneumonia BacterialMANAGEMENTHumanspneumoniaBACTERIAL PNEUMONIAImmunocompromiseAgedAcquired Immunodeficiency Syndromebusiness.industrymicrobiologyBacterial pneumoniaAustraliaPneumoniamedicine.diseaseMultidrug-resistant pathogensPneumoniamultidrug-resistant pathogensMycosesBacteremiaAfricaEtiologyRISK-FACTORSimmunocompromiseAmericasbusinessClinical Infectious Diseases
researchProduct

Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study

2016

BACKGROUND: Antibiotic resistance is a major global health problem and pathogens such as meticillin-resistant Staphylococcus aureus (MRSA) have become of particular concern in the management of lower respiratory tract infections. However, few data are available on the worldwide prevalence and risk factors for MRSA pneumonia. We aimed to determine the point prevalence of MRSA pneumonia and identify specific MRSA risk factors in community-dwelling patients hospitalised with pneumonia.METHODS: We did an international, multicentre study of community-dwelling, adult patients admitted to hospital with pneumonia who had microbiological tests taken within 24 h of presentation. We recruited investig…

Maleantibiotic resistancePrevalenceMRSAmedicine.disease_causepneumonia; antibiotic resistance; staphylococcus aureus; MRSAGlobal HealthCohort Studies0302 clinical medicineCommunity-acquired pneumoniaRisk FactorsRetrospective StudiePrevalenceCommunity-Acquired Infection030212 general & internal medicineeducation.field_of_studyCross InfectionRespiratory tract infectionsMethicillin-Resistant Staphylococcus aureuStaphylococcal InfectionsHospitalsCommunity-Acquired InfectionsInfectious DiseasesInfectious diseasesFemaleHumanMethicillin-Resistant Staphylococcus aureusstaphylococcus aureusmedicine.medical_specialtyPopulationAdmissionstaphylococcus aureuSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesHospitalInternal medicinemedicineHumanspneumoniaRisk factoreducationIntensive care medicineStaphylococcal InfectionRetrospective StudiesAgedbusiness.industryRisk FactorOdds ratioPneumoniamedicine.diseaseMethicillin-resistant Staphylococcus aureusPneumonia030228 respiratory systemMethicillin ResistanceCohort Studiebusiness
researchProduct

Quality standards for the management of bronchiectasis in Italy: A national audit

2016

Although historically considered a neglected disease, bronchiectasis has become a disease of renewed interest over recent decades in light of an increase in prevalence and a substantial burden on healthcare systems. In 2010, the British Thoracic Society (BTS) published guidelines on the management of bronchiectasis in adults, along with specific quality standards. To date, these represent the only quality standards available in Europe. These have been tested over a number of years in the UK with progressive improvements in the standard of care. No national guidelines are available in Italy and no indications on which guideline should be followed have been given by the Italian Society of Res…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtybronchiectasismedia_common.quotation_subjectSymptom Flare UpMedical auditSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciences0302 clinical medicinemedicinePrevalenceHumansQuality (business)Pseudomonas Infections030212 general & internal medicineIntensive care medicineNational auditmedia_commonAgedMedical AuditBronchiectasisbusiness.industryMedicine (all)Middle Agedmedicine.diseaseSymptom Flare UpAnti-Bacterial AgentsPatient Care Management030228 respiratory systemItalyNeeds assessmentPseudomonas aeruginosaFemalebusinessMedicine (all); Pulmonary and Respiratory MedicineNeeds Assessment
researchProduct